Terms: = Ovarian cancer AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1 AND Treatment
56 results:
1. Overexpression of ABCC1 and abcg2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor.
Teng QX; Lei ZN; Wang JQ; Yang Y; Wu ZX; Acharekar ND; Zhang W; Yoganathan S; Pan Y; Wurpel J; Chen ZS; Fang S
Drug Resist Updat; 2024 Mar; 73():101028. PubMed ID: 38340425
[TBL] [Abstract] [Full Text] [Related]
2. The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene abcg2 in ovarian cancer.
McFadden M; Singh SK; Kinnel B; Varambally S; Singh R
J Ovarian Res; 2023 Nov; 16(1):220. PubMed ID: 37990267
[TBL] [Abstract] [Full Text] [Related]
3. CD109 Promotes Drug Resistance in A2780 ovarian cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
Kim JS; Shin MJ; Lee SY; Kim DK; Choi KU; Suh DS; Kim D; Kim JH
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373457
[TBL] [Abstract] [Full Text] [Related]
4. Genetically Engineered Artificial Exosome-Constructed Hydrogel for ovarian cancer Therapy.
Li Q; Song Q; Zhao Z; Lin Y; Cheng Y; Karin N; Luan Y
ACS Nano; 2023 Jun; 17(11):10376-10392. PubMed ID: 37194951
[TBL] [Abstract] [Full Text] [Related]
5. Piperine Targets Different Drug Resistance Mechanisms in Human ovarian cancer Cell Lines Leading to Increased Sensitivity to Cytotoxic Drugs.
Wojtowicz K; Sterzyńska K; Świerczewska M; Nowicki M; Zabel M; Januchowski R
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921897
[TBL] [Abstract] [Full Text] [Related]
6. Aberrant activation of Wnt/catenin signaling and overexpression of abcg2 contributes to apoptosis down regulation and tumor progression of high grade ovarian cancer.
Gui Z; Yan H; Wu J; Zhang M; Wu A; He J
Acta Biochim Pol; 2021 Feb; 68(1):127-133. PubMed ID: 33635609
[TBL] [Abstract] [Full Text] [Related]
7. A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells.
Rong D; Wang C; Zhang X; Wei Y; Zhang M; Liu D; Farhan H; Momen Ali SA; Liu Y; Taouil A; Guo W; Wang Y; Ojima I; Yang S; Wang H
Cancer Lett; 2020 Oct; 491():36-49. PubMed ID: 32730778
[TBL] [Abstract] [Full Text] [Related]
8. The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes.
Eid SY; Althubiti MA; Abdallah ME; Wink M; El-Readi MZ
Phytomedicine; 2020 Oct; 77():153280. PubMed ID: 32712543
[TBL] [Abstract] [Full Text] [Related]
9. Adipocytes induce the resistance of ovarian cancer to carboplatin through ANGPTL4.
Zhou S; Wang R; Xiao H
Oncol Rep; 2020 Sep; 44(3):927-938. PubMed ID: 32705217
[TBL] [Abstract] [Full Text] [Related]
10. A novel c-Kit/phospho-prohibitin axis enhances ovarian cancer stemness and chemoresistance via Notch3-PBX1 and β-catenin-abcg2 signaling.
Fang CH; Lin YT; Liang CM; Liang SM
J Biomed Sci; 2020 Mar; 27(1):42. PubMed ID: 32169072
[TBL] [Abstract] [Full Text] [Related]
11. 3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function.
Jin L; Yingchun W; Zhujun S; Yinan W; Dongchen W; Hui Y; Xi Y; Wanzhou Z; Buluan Z; Jinhua W
Biomed Pharmacother; 2019 Aug; 116():108992. PubMed ID: 31129513
[TBL] [Abstract] [Full Text] [Related]
12. Human recombinant FSH induces chemoresistance in human breast cancer cells via HIF-1α activation†.
Bergandi L; Canosa S; Pittatore G; Silvagno F; Doublier S; Gennarelli G; Benedetto C; Revelli A
Biol Reprod; 2019 Jun; 100(6):1521-1535. PubMed ID: 30939201
[TBL] [Abstract] [Full Text] [Related]
13. Hypoxia-inducible factor-2α directly promotes bcrp expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M
Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571
[TBL] [Abstract] [Full Text] [Related]
14. SLC27A2 regulates miR-411 to affect chemo-resistance in ovarian cancer.
Chen FD; Chen HH; Ke SC; Zheng LR; Zheng XY
Neoplasma; 2018 Nov; 65(6):915-924. PubMed ID: 30334452
[TBL] [Abstract] [Full Text] [Related]
15. Scutellaria baicalensis targets the hypoxia-inducible factor-1α and enhances cisplatin efficacy in ovarian cancer.
Hussain I; Waheed S; Ahmad KA; Pirog JE; Syed V
J Cell Biochem; 2018 Sep; 119(9):7515-7524. PubMed ID: 29797601
[TBL] [Abstract] [Full Text] [Related]
16. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
Li Y; Sun J; Gao S; Hu H; Xie P
Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
[TBL] [Abstract] [Full Text] [Related]
17. New and Old Genes Associated with Primary and Established Responses to Paclitaxel treatment in ovarian cancer Cell Lines.
Świerczewska M; Klejewski A; Brązert M; Kaźmierczak D; Iżycki D; Nowicki M; Zabel M; Januchowski R
Molecules; 2018 Apr; 23(4):. PubMed ID: 29649113
[TBL] [Abstract] [Full Text] [Related]
18. Novel potential photodynamic therapy strategy using 5-Aminolevulinic acid for ovarian clear-cell carcinoma.
Teshigawara T; Mizuno M; Ishii T; Kitajima Y; Utsumi F; Sakata J; Kajiyama H; Shibata K; Ishizuka M; Kikkawa F
Photodiagnosis Photodyn Ther; 2018 Mar; 21():121-127. PubMed ID: 29196245
[TBL] [Abstract] [Full Text] [Related]
19. MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
Zanotti L; Romani C; Tassone L; Todeschini P; Tassi RA; Bandiera E; Damia G; Ricci F; Ardighieri L; Calza S; Marchini S; Beltrame L; Tognon G; D'Incalci M; Pecorelli S; Sartori E; Odicino F; Ravaggi A; Bignotti E
BMC Cancer; 2017 May; 17(1):366. PubMed ID: 28545541
[TBL] [Abstract] [Full Text] [Related]
20. Enhancement of the Effect of Methyl Pyropheophorbide-a-Mediated Photodynamic Therapy was Achieved by Increasing ROS through Inhibition of Nrf2-HO-1 or Nrf2-abcg2 Signaling.
Tian S; Yong M; Zhu J; Zhang L; Pan L; Chen Q; Li KT; Kong YH; Jiang Y; Yu TH; Yu LH; Bai DQ
Anticancer Agents Med Chem; 2017; 17(13):1824-1836. PubMed ID: 28356018
[TBL] [Abstract] [Full Text] [Related]
[Next]
